ReCode Therapeutics is pioneering advancements in genetic medicine through its innovative Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform. This first-in-class technology is designed to enhance the delivery of genetic therapeutics, such as mRNA and gene correction agents, to specific organs and tissues beyond the liver, which is a common limitation of traditional delivery systems. By incorporating a unique fifth lipid, the SORT LNPs can effectively direct therapeutic agents to targeted sites like the lungs and spleen, thereby optimizing treatment for genetically defined diseases. This precision delivery capability is complemented by the versatility of the platform, allowing for various routes of administration, including inhaled, intravenous, and intrathecal methods.

ReCode's therapeutic pipeline focuses on rare genetic disorders, with investigational therapies such as RCT1100 for primary ciliary dyskinesia (PCD) and RCT2100 for cystic fibrosis (CF). Both therapies utilize inhaled mRNA-based approaches tailored to address specific genetic mutations that lack effective treatment options. The SORT LNP technology not only facilitates the delivery of these mRNA candidates but also holds promise for broader applications across a range of genetic diseases, including those affecting the central nervous system, liver, and musculoskeletal systems. This innovative approach aims to provide disease-modifying and corrective therapies, potentially transforming the landscape of treatment for patients with rare genetic conditions.

United States

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Digestive System Diseases

Genetic Diseases

Infectious Diseases

Liver Diseases

Lung Diseases

ReCode Therapeutics

Primary ciliary dyskinesia

ReCode Drug Candidate #1

Biologics

Cystic fibrosis

ReCode Drug Candidate #2

Gene Therapy

Surfactant deficiencies

ReCode Drug Candidate #3

Vaccines

ReCode Drug Candidate #4

Severe alpha-1 antitrypsin deficiency

ReCode Drug Candidate #5

Texas

Personalized Medicine

Therapeutic

ReCode Therapeutics

Company Details